Catalent
CTLT

Delisted

CTLT was delisted on the 19th of December, 2024.

Back to rankings

Healthcare Pharmaceutical Preparations

Financial journalist opinion

Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400

NEW YORK , Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE: LII) will replace Catalent Inc. (NYSE: CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE: BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December 18.

Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400

Novo Holdings completes $16.5 bln takeover of Catalent

Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled.

Novo Holdings completes $16.5 bln takeover of Catalent

Novo Holdings Completes Acquisition of Catalent

SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that Novo Holdings has completed its previously announced acquisition of Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion. Alessandro Maselli, who will remain President and Chie.

Novo Holdings Completes Acquisition of Catalent

Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say

All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.

Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction

SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now expect to close the transaction in the coming days. “Today represents an important step in our t.

Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk's subsequent acquisition of three manufacturing sites from Novo Holdings A/S.

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction

SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the European Commission (EC) has granted unconditional approval for the pending transaction under which Novo Holdings will acquire Catalent. “We are pleased to have received European Commission approval, whic.

Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction

Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval

Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.

Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval

Zacks Investment Research

Why Is Catalent (CTLT) Up 3.2% Since Last Earnings Report?

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

Why Is Catalent (CTLT) Up 3.2% Since Last Earnings Report?

See News Rankings

Charts implemented using Lightweight Charts™